결핵 진료지침
87. Von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag Jr V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med 2019;7:249–59.
88. Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur Respir J 2018;51:1800017.
89. Kuksa L, Barkane L, Hittel N, Gupta R. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens. Eur Respir J 2017;50:1701105.
90. Hafkin J, Hittel N, Martin A, Gupta R. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J 2017;50:1700311.
91. Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, et al. Six-month response to delamanid treatment in MDR TB patients. Emerg Infect Dis 2017;23:1746–48.
92. Chang KC, Leung ECC, Law WS, Leung WM, Tai LB, Lee SN, et al. Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong. Eur Respir J 2018;51:1800159.
93. Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis 2018;18:536–44.
94. Häcker B, Schönfeld N, Krieger D, Otto-Knapp R, Hittel N, Pflugmacher P, et al. Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany. Eur Respir J 2020;2000009.
Ⅲ. 약제내성결핵의 치료 141